AstraZeneca, MSD’s Lynparza combo gets FDA nod for prostate cancer treatment
Lynparza is a PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Jun 23
Lynparza is a PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours…
02 Jun 23
The European approval is based on Phase 3 data from the SUNSHINE and SUNRISE trials which enrolled more…
02 Jun 23
SYMPLIFY Results Demonstrate Strong Performance of GRAIL’s Multi-Cancer Early Detection Methylation-Based Platform in Individuals Presenting With Non-Specific Signs…
02 Jun 23
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with…
01 Jun 23
In the trial, the number of new gadolinium-enhancing (GdE) T1-lesions was lowered by 89% and 79% in the…
01 Jun 23
The phase 2 study was evaluating upadacitinib 30mg alone and in combination (ABBV-599 high dose) in systemic lupus…
01 Jun 23
The scientists found that the disorder has an overactive version of the STAT4 protein, which controls inflammation and…
31 May 23
In the late-stage trial, the prophylactic treatment with marstacimab showed a statistically significant and clinically relevant reduction in…
31 May 23
Health Canada approved BRUKINSA based on positive efficacy results and a favourable safety profile from two global late-stage…
31 May 23
DMD is the most common form of muscular dystrophy and is a genetic disorder characterised by progressive muscle…